Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Nov 19, 2025; 15(11): 108964
Published online Nov 19, 2025. doi: 10.5498/wjp.v15.i11.108964
Published online Nov 19, 2025. doi: 10.5498/wjp.v15.i11.108964
Polymorphic variants in GABA-A receptor and their association with epilepsy and drug resistance: A North Indian cohort study
Pradeep Kumar Dabla, Swati Singh, Aroop Viswas, Department of Biochemistry, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research, New Delhi 110002, Delhi, India
Swapan Gupta, Department of Neurology, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research, New Delhi 110002, Delhi, India
Manisha Yadav, Subash C Sonkar, Bidhan C Koner, Multi-disciplinary Research Unit, Maulana Azad Medical College, New Delhi 110002, Delhi, India
Bidhan C Koner, Department of Biochemistry, Maulana Azad Medical College, New Delhi 110002, Delhi, India
Nafija Serdarevic, Institute for Clinical Chemistry and Biochemistry, University of Sarajevo Clinics Center, Sarajevo 71000, Bosnia and Herzegovina
Author contributions: Dabla PK designed and supervised the study, provided facilities for biochemical testing, contributed in data interpretation and preparation and revision of the manuscript; Singh S performed data analysis and drafted the manuscript; Viswas A conducted the experiments and contributed in data collection; Gupta S provided the facility for the enrolment of patients; Yadav M and Sonkar SC helped in performing genetic analysis; Konar BC provided facility for molecular testing; Serdarevic N helped in critical review and data analysis; and all authors have reviewed the entire content of this manuscript and approved for the submission.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Maulana Azad Medical College and Associated Hospitals, approval F1/IEC/MAMC/82/10/2020/No. 225.
Informed consent statement: Informed consent was obtained from all individual participants included in the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Data is available from the corresponding author on request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Pradeep Kumar Dabla, MD, Professor, Department of Biochemistry, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research, 1 Jawaharlal Nehru Marg, 64 Khamba, Raj Ghat, New Delhi 110002, Delhi, India.
Received: April 27, 2025
Revised: May 25, 2025
Accepted: September 1, 2025
Published online: November 19, 2025
Processing time: 190 Days and 24 Hours
Revised: May 25, 2025
Accepted: September 1, 2025
Published online: November 19, 2025
Processing time: 190 Days and 24 Hours
Core Tip
Core Tip: The limited available data have shown association of gamma-aminobutyric acid (GABA) receptors as a key target in the pathophysiology of epilepsy. Prior studies have hypothesized that polymorphism in genes that encode the α1 and γ2 subunits of the GABA-A receptor protein, alters the channel’s structure-function, potentially leading to medication resistance. However, limited data is available on the relationship between GABA receptor variants and drug resistance in human subjects. In our present study, we aim to elucidate the role of GABA-A subunit variants in the development of anti-epileptic drug resistance, which could inform more personalized treatment strategies for individuals with epilepsy, ultimately improving their health outcomes.